| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a chemical linker, t-Boc-N-amido-PEG1-acid does not have a specific biological target. The terminal carboxylic acid can form amide bonds with primary amines, while the Boc-protected amino group can be deprotected under acidic conditions for further conjugation. The PEG1 spacer provides solubility and flexibility.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1]. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [2].
In vitro activity is not assessed for this compound as it is a chemical linker rather than a bioactive molecule. Its reactivity and utility in organic synthesis and bioconjugation are the primary focus. The compound can participate in amide bond formation and is used in the synthesis of PROTAC molecules. |
| ln Vivo |
In vivo activity is not applicable for t-Boc-N-amido-PEG1-acid as it is not a pharmacologically active compound. It is used as a chemical intermediate and linker in drug delivery systems to improve pharmacokinetics and biodistribution. It is not intended for therapeutic use.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically performed for t-Boc-N-amido-PEG1-acid, as it is a chemical linker rather than a bioactive compound. Its purity and chemical properties are characterized by standard analytical techniques including NMR, HPLC, and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays are not applicable for t-Boc-N-amido-PEG1-acid as it is not a pharmacologically active compound. It is used in chemical synthesis and bioconjugation and is not evaluated for its effects on cell viability or other cellular functions.
|
| Animal Protocol |
In vivo animal studies are not performed for t-Boc-N-amido-PEG1-acid as it is not a pharmacologically active compound. Any animal studies involving this compound would be limited to evaluating the pharmacokinetics of PEG-conjugated molecules.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of t-Boc-N-amido-PEG1-acid are not characterized as it is not a drug candidate. The compound is soluble in DMSO and other organic solvents. It is stored at -20°C for long-term stability. The compound's reactivity with water necessitates careful handling.
|
| Toxicity/Toxicokinetics |
Toxicity data for t-Boc-N-amido-PEG1-acid are limited to standard safety data sheets for handling and occupational exposure. The compound is for research use only and is not intended for human or veterinary use. Appropriate safety precautions should be taken during handling.
|
| References | |
| Additional Infomation |
t-Boc-N-amido-PEG1-acid is a PEG-based PROTAC linker containing a terminal carboxylic acid and a Boc-protected amino group. It is a monodisperse heterobifunctional PEG1 linker used in PROTAC synthesis and bioconjugation. The compound is intended for laboratory research use only.
|
| Molecular Formula |
C10H19NO5
|
|---|---|
| Molecular Weight |
233.261563539505
|
| Exact Mass |
233.126
|
| CAS # |
1260092-44-1
|
| PubChem CID |
23591750
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
385.0±27.0 °C at 760 mmHg
|
| Flash Point |
186.7±23.7 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.463
|
| LogP |
0.93
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
16
|
| Complexity |
234
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YGNSGMAPLOVGIU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H19NO5/c1-10(2,3)16-9(14)11-5-7-15-6-4-8(12)13/h4-7H2,1-3H3,(H,11,14)(H,12,13)
|
| Chemical Name |
3-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2871 mL | 21.4353 mL | 42.8706 mL | |
| 5 mM | 0.8574 mL | 4.2871 mL | 8.5741 mL | |
| 10 mM | 0.4287 mL | 2.1435 mL | 4.2871 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
